Interface Biologics' CSO Paul Santerre receives NSERC Synergy Innovation Award from Governor General

TORONTO, ONTARIO--(Marketwire - March 5, 2013) -

Editors Note: There is a photo associated with this press release.

Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce that Dr. Paul Santerre, PhD, Chief Scientific Officer at IBI, was presented with a Synergy Award for Innovation by His Excellency the Right Honourable David Johnston, Governor General of Canada during a Natural Sciences and Engineering Research Council of Canada (NSERC) Awards ceremony at Rideau Hall on February 27th.

Interface Biologics was founded by Dr. Santerre, and is based on his groundbreaking work at the University of Toronto's Institute of Biomaterials and Biomedical Engineering. Together, they have produced transformative biomedical polymers that improve the biocompatibility of medical devices, making them safer and more effective. Last year, IBI's licensing partner, Angiodynamics, received FDA Clearance for BioFlo™ PICC with IBI's Endexo™ technology.

"The Synergy Awards for Innovation recognize outstanding achievements that have resulted from partnerships between university researchers and industry," said Suzanne Fortier, President of NSERC. "These awards honour collaboration as the foundation of achievement and highlight Canadian innovations." The NSERC Synergy Awards include money for a research grant as well as funding to hire an NSERC Industrial R&D Fellow for two years.

"We are honoured to have been selected by NSERC for this prestigious Synergy Award. We continue to develop biomedical polymer technologies that can be applied to a myriad of clinical applications and this award is recognition of the winning partnership between Professor Santerre, the University of Toronto, Interface Biologics and our commercial licensees. In conjunction with Professor Santerre and his lab, we will be using the proceeds from the grant to continue to develop innovative technologies that can increase the safety and effectiveness of medical devices," commented Tom Reeves, President and CEO of Interface Biologics.

"Investing in science and technology has a direct impact on Canadians," said the Honourable Gary Goodyear, Minister of State (Science and Technology). "The achievements of the top researchers honoured today, and the successful partnerships they have forged with the business community, demonstrate how our investments in research create high-value jobs and help build a stronger, more prosperous country."

About Interface Biologics Inc.

Interface Biologics (IBI) is an early commercial stage privately held company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. IBI's primary technology focus areas are anti-thrombogenic devices that reduce thrombosis and programmable combination drug delivery devices. For more information about Interface Biologics, please visit www.interfacebiologics.com.

To view the photo associated with this press release, please visit the following link: http://www.marketwire.com/library/20130304-IBimageLG.jpg.